Technical Analysis for RETA - Reata Pharmaceuticals, Inc. - Class A

Grade Last Price % Change Price Change
grade A 76.39 4.44% 3.25
RETA closed unchanged on Thursday, January 17, 2019, on 27 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical RETA trend table...

Date Alert Name Type % Chg
Jan 17 180 Bullish Setup Bullish Swing Setup 4.44%
Jan 17 Wide Bands Range Expansion 4.44%
Jan 17 Overbought Stochastic Strength 4.44%
Jan 16 Narrow Range Bar Range Contraction 4.44%
Jan 16 NR7 Range Contraction 4.44%
Jan 16 Wide Bands Range Expansion 4.44%
Jan 16 Overbought Stochastic Strength 4.44%
Jan 15 Spinning Top Other 4.95%
Jan 15 Calm After Storm Range Contraction 4.95%
Jan 15 Wide Bands Range Expansion 4.95%

Older signals for RETA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company focuses on drugs with novel mechanisms of action that modulate regulatory proteins called transcription factors. Its lead product candidates include bardoxolone methyl and RTA 408, which are members of a class of small molecules called antioxidant inflammation modulators. It is involved in LARIAT, a Phase II study of bardoxolone methyl for the treatment of pulmonary arterial hypertension and pulmonary hypertension due to interstitial lung disease. RTA 408 is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia and mitochondrial myopathies. Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.
Is RETA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 99.5
52 Week Low 19.31
Average Volume 236,268
200-Day Moving Average 55.0567
50-Day Moving Average 61.879
20-Day Moving Average 61.904
10-Day Moving Average 71.009
Average True Range 4.4761
ADX 27.31
+DI 29.7134
-DI 16.0431
Chandelier Exit (Long, 3 ATRs ) 63.8667
Chandelier Exit (Short, 3 ATRs ) 60.9283
Upper Bollinger Band 81.2712
Lower Bollinger Band 42.5368
Percent B (%b) 0.79
BandWidth 62.571724
MACD Line 3.985
MACD Signal Line 2.4396
MACD Histogram 1.5454
Fundamentals Value
Market Cap 1.91 Billion
Num Shares 26.1 Million
EPS -1.06
Price-to-Earnings (P/E) Ratio -69.00
Price-to-Sales 15.55
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 76.79
Resistance 3 (R3) 76.43 74.87 76.18
Resistance 2 (R2) 74.87 73.94 75.04 75.97
Resistance 1 (R1) 74.00 73.36 74.44 74.36 75.77
Pivot Point 72.44 72.44 72.65 72.61 72.44
Support 1 (S1) 71.57 71.51 72.01 71.93 70.51
Support 2 (S2) 70.01 70.93 70.18 70.31
Support 3 (S3) 69.14 70.01 70.10
Support 4 (S4) 69.50